Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 EvolusVerastemANI PharmaceuticalsVerrica PharmaceuticalsAeglea BioTherapeutics
SymbolNASDAQ:EOLSNASDAQ:VSTMNASDAQ:ANIPNASDAQ:VRCANASDAQ:AGLE
Price Information
Current Price$13.58$2.68$31.86$13.76$7.71
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.11.11.91.41.7
Analysis Score2.21.53.32.43.5
Community Score2.82.62.52.32.7
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.72.51.7
Earnings & Valuation Score0.60.61.90.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$13.89$3.00$46.00$16.50$12.67
% Upside from Price Target2.27% upside11.94% upside44.38% upside19.91% upside64.29% upside
Trade Information
Market Cap$593.89 million$473.80 million$393.95 million$350.07 million$370.20 million
Beta2.690.721.342.31.66
Average Volume1,526,0632,953,34358,222108,788219,801
Sales & Book Value
Annual Revenue$34.92 million$17.46 million$206.55 millionN/A$3.89 million
Price / Sales17.0126.351.91N/A95.17
CashflowN/AN/A$8.03 per shareN/AN/A
Price / CashN/AN/A3.97N/AN/A
Book Value$2.38 per share$0.09 per share$17.59 per share$2.52 per share$2.07 per share
Price / Book5.7129.781.81N/A3.72
Profitability
Net Income$-90,030,000.00$-149,210,000.00$6.09 million$-28,210,000.00$-78,250,000.00
EPS($3.19)($2.00)$4.46($1.13)($2.45)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/A9.10N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-120.63%-590.19%-11.92%N/AN/A
Return on Equity (ROE)-121.11%-189.37%19.01%-54.53%-81.42%
Return on Assets (ROA)-30.91%-67.69%8.15%-40.42%-66.88%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.25%0.45%0.90%N/AN/A
Current Ratio10.42%5.02%2.18%2.15%10.06%
Quick Ratio10.03%4.80%1.40%2.15%10.06%
Ownership Information
Institutional Ownership Percentage21.66%42.15%53.40%33.97%80.87%
Insider Ownership Percentage10.10%2.90%24.80%40.20%13.70%
Miscellaneous
Employees125483691787
Shares Outstanding43.73 million171.67 million12.37 million25.44 million48.02 million
Next Earnings Date5/10/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
finance.yahoo.com - April 1 at 5:58 PM
Immedica obtains exclusive commercialization rights in Europe and several Middle Eastern countriesImmedica obtains exclusive commercialization rights in Europe and several Middle Eastern countries
morningstar.com - March 22 at 10:31 AM
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle EastAeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
finance.yahoo.com - March 22 at 10:31 AM
Aeglea BioTherapeutics (NASDAQ:AGLE) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSAeglea BioTherapeutics (NASDAQ:AGLE) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
americanbankingnews.com - March 19 at 8:14 AM
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate HighlightsAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
finance.yahoo.com - March 18 at 12:34 PM
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of DirectorsAeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
finance.yahoo.com - February 24 at 5:03 PM
We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth CarefullyWe Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 18 at 9:29 AM
AGLE Feb 2021 7.500 callAGLE Feb 2021 7.500 call
ca.finance.yahoo.com - January 23 at 5:00 PM
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceAeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 4:41 PM
Aeglea (AGLE) Upgraded to Buy: Heres WhyAeglea (AGLE) Upgraded to Buy: Here's Why
finance.yahoo.com - December 30 at 12:55 PM
Is AGLE A Good Stock To Buy Now According To Hedge Funds?Is AGLE A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 19 at 12:41 AM
Aeglea BioTherapeutics Appoints Alison Lawton to Board of DirectorsAeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
finance.yahoo.com - December 17 at 6:36 PM
Aeglea Bios ACN00177 nabs Rare Pediatric status for inherited metabolic disorderAeglea Bio's ACN00177 nabs Rare Pediatric status for inherited metabolic disorder
seekingalpha.com - December 1 at 4:27 PM
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of HomocystinuriaAeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
finance.yahoo.com - December 1 at 8:33 AM
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor ConferencesAeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
finance.yahoo.com - November 17 at 5:57 PM
How Much Are Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Spending On Buying Shares?How Much Are Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Spending On Buying Shares?
finance.yahoo.com - November 10 at 8:26 AM
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate HighlightsAeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
markets.businessinsider.com - November 5 at 9:12 AM
Aeglea: 3Q Earnings SnapshotAeglea: 3Q Earnings Snapshot
mysanantonio.com - November 5 at 9:12 AM
Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?Is a Surprise Coming for Aeglea (AGLE) This Earnings Season?
finance.yahoo.com - November 3 at 9:50 AM
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of HomocystinuriaAeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
finance.yahoo.com - October 26 at 8:52 AM
Epirium Bio Appoints Alexander Casdin, Reneo Capital Management Founder, as Chief Financial OfficerEpirium Bio Appoints Alexander Casdin, Reneo Capital Management Founder, as Chief Financial Officer
morningstar.com - October 13 at 4:25 PM
Hedge Funds Are Crazy About Aeglea BioTherapeutics, Inc. (AGLE)Hedge Funds Are Crazy About Aeglea BioTherapeutics, Inc. (AGLE)
news.yahoo.com - October 13 at 4:25 PM
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical MeetingsAeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
apnews.com - October 6 at 12:44 PM
Is Aeglea BioTherapeutics (NASDAQ:AGLE) In A Good Position To Invest In Growth?Is Aeglea BioTherapeutics (NASDAQ:AGLE) In A Good Position To Invest In Growth?
finance.yahoo.com - September 11 at 7:31 AM
Aeglea BioTherapeutics to Participate in September Investment ConferencesAeglea BioTherapeutics to Participate in September Investment Conferences
finance.yahoo.com - September 2 at 5:40 PM
DateCompanyBrokerageAction
4/8/2021EvolusHC WainwrightBoost Price Target
3/30/2021EvolusMizuhoBoost Price Target
2/24/2021EvolusTruist FinancialDowngrade
2/22/2021EvolusBarclaysBoost Price Target
2/22/2021EvolusCantor FitzgeraldBoost Price Target
2/19/2021EvolusStifel NicolausBoost Price Target
7/7/2020EvolusSunTrust BanksLower Price Target
4/30/2020EvolusWells Fargo & CompanyLower Price Target
8/2/2019VerastemB. RileySet Price Target
6/20/2019VerastemBTIG ResearchDowngrade
5/14/2019VerastemRoth CapitalLower Price Target
5/10/2019VerastemRaymond JamesDowngrade
7/27/2018VerastemSeaport Global SecuritiesSet Price Target
4/30/2020ANI PharmaceuticalsGuggenheimLower Price Target
5/13/2019ANI PharmaceuticalsCanaccord GenuityReiterated Rating
7/24/2020Verrica PharmaceuticalsNorthland SecuritiesReiterated Rating
7/15/2020Verrica PharmaceuticalsBank of AmericaDowngrade
6/30/2020Verrica PharmaceuticalsNeedham & Company LLCLower Price Target
7/10/2018Verrica PharmaceuticalsCowenInitiated Coverage
7/10/2018Verrica PharmaceuticalsJefferies Financial GroupInitiated Coverage
10/23/2020Aeglea BioTherapeuticsLifesci CapitalReiterated Rating
5/4/2020Aeglea BioTherapeuticsPiper SandlerInitiated Coverage
3/21/2019Aeglea BioTherapeuticsJPMorgan Chase & Co.Initiated Coverage
6/14/2018Aeglea BioTherapeuticsBMO Capital MarketsInitiated Coverage
4/24/2018Aeglea BioTherapeuticsEvercore ISIInitiated Coverage
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.